학술논문
Effect of Minimally Invasive Surfactant Therapy Versus Sham Treatment on Death or Bronchopulmonary Dysplasia in Preterm Infants With Respiratory Distress Syndrome The OPTIMIST: A Randomized Clinical Trial
Document Type
Academic Journal
Author
Dargaville, P.A.; Kamlin, O.F.; Orsini, F.; Wang, X.; De Paoli, A.G.; Kanmaz Kutman, H.G.; Cetinkaya, M.; Aiyappan, A.; Lemyre, B.; Kuo, S.; Rajadurai, V.S.; O’Shea, J.; Biniwale, M.; Ramanathan, R.; Kushnir, A.; Bader, D.; Thomas, M.R.; Mallinath, C.; Buksh, M.J.; Bhatia, R.; Sullivan, C.L.; Shinwell, E.S.; Dyson, A.; Barker, D.P.; Kugelman, A.; Donovan, T.J.; Tauscher, M.K.; Murthy, V.; Ali, S.K.M.; Yossuck, P.; Clark, H.W.; Soll, R.F.; Carlin, J.B.; Davis, P.G.
Source
Obstetric Anesthesia Digest. Sep 01, 2022 42(3):138-139
Subject
Language
English
ISSN
0275-665X
Abstract
(JAMA. 2021;326:2478–2487)Continuous positive airway pressure (CPAP) is recommended for newly born preterm infants. A previous meta-analysis of clinical trials compared CPAP to intubation and ventilation in terms of death or bronchopulmonary dysplasia and found CPAP had a relative risk of 0.91 [95% confidence interval (CI), 0.84-0.99]. In the studies used in meta-analysis, exogenous surfactant was administered only to infants with relatively high levels of inspired oxygen. This study, the OPTIMIST-A trial aimed to determine whether minimally invasive surfactant therapy, using a thin catheter, would lower the incidence of death and/or bronchopulmonary dysplasia.